CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 31 enrolled
Drug / intervention
AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1 +3 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01257217
NCT01257217N/ACompleted

A Randomized, Subject-Masked Comparison of Visual Function After Bilateral Implantation of Presbyopia-Correcting IOLs

Alcon Research·interventional·Posted Dec 9, 2010·Updated Jul 2, 2018

In Brief

A clinical study evaluating AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1, AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL Model SND1TT, and 2 other interventions for Cataract. Completed, enrolled 31 participants.

Detailed Summary

The purpose of this study is to evaluate visual and refractive parameters in a series of subjects bilaterally implanted with presbyopia-correcting intraocular lenses (IOLs) during cataract surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 9, 2010
Enrollment StartNov 1, 2010
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 15.6 years ago

Interventions

AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1device

Multifocal IOL implanted for long-term use over the lifetime of the cataract patient

AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL Model SND1TTdevice

Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient

Acri.LISA® 366D IOLdevice

Aspheric diffractive IOL with +3.75 D add power implanted for long-term use over the lifetime of the cataract patient

Acri.LISA® 466TD Toric IOLdevice

Aspheric diffractive IOL with +3.75 D add power and astigmatism correction implanted for long-term use over the lifetime of the cataract patient